- Home
- ATOS vs OPAL Comparison
ATOS vs OPAL Comparison
Compare ATOS & OPAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- OPAL
- Stock Information
- Founded
- ATOS 2009
- OPAL 1998
- Country
- ATOS United States
- OPAL United States
- Employees
- ATOS N/A
- OPAL N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- OPAL Natural Gas Distribution
- Sector
- ATOS Health Care
- OPAL Utilities
- Exchange
- ATOS Nasdaq
- OPAL Nasdaq
- Market Cap
- ATOS 96.8M
- OPAL 88.1M
- IPO Year
- ATOS 2012
- OPAL N/A
- Fundamental
- Price
- ATOS $0.65
- OPAL $1.70
- Analyst Decision
- ATOS Strong Buy
- OPAL Buy
- Analyst Count
- ATOS 3
- OPAL 5
- Target Price
- ATOS $7.00
- OPAL $5.70
- AVG Volume (30 Days)
- ATOS 520.3K
- OPAL 205.7K
- Earning Date
- ATOS 03-25-2025
- OPAL 05-08-2025
- Dividend Yield
- ATOS N/A
- OPAL N/A
- EPS Growth
- ATOS N/A
- OPAL N/A
- EPS
- ATOS N/A
- OPAL 0.02
- Revenue
- ATOS N/A
- OPAL $299,972,000.00
- Revenue This Year
- ATOS N/A
- OPAL $29.17
- Revenue Next Year
- ATOS N/A
- OPAL $17.36
- P/E Ratio
- ATOS N/A
- OPAL $84.75
- Revenue Growth
- ATOS N/A
- OPAL 17.13
- 52 Week Low
- ATOS $0.65
- OPAL $1.68
- 52 Week High
- ATOS $2.31
- OPAL $5.18
- Technical
- Relative Strength Index (RSI)
- ATOS 31.82
- OPAL 23.11
- Support Level
- ATOS $0.66
- OPAL $1.87
- Resistance Level
- ATOS $0.71
- OPAL $1.98
- Average True Range (ATR)
- ATOS 0.04
- OPAL 0.14
- MACD
- ATOS -0.00
- OPAL 0.00
- Stochastic Oscillator
- ATOS 0.00
- OPAL 2.90
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About OPAL OPAL Fuels Inc.
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.